Ability Biologics Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ability Biologics Inc. - overview
Established
2023
Location
Montreal, QC, Canada
Primary Industry
Biotechnology
About
Founded in 2023 and based in Montreal, Quebec, Canada, Ability Biologics Inc. , also known as Ability, operates as a premier cell targeting company that offers therapeutic solutions. The company was founded by its CEO, Giles Day. In December 2023, Ability Biologics Inc.
raised USD 12 million in seed funding led by Amplitude, Fonds de solidarité FTQ, Charles River Laboratories, Alexandria Venture Investments, and PageOne. vc. Ability Biologics provides AI-based drug discovery and therapeutic solutions. The company also offers the AbiLeap discovery platform, which is a machine learning-based antibody therapeutics discovery platform that discovers and develops human antibodies, mainly IgG-based multispecific antibodies.
In addition, the company also develops preclinical antibody candidates and immune modulators for various therapeutic applications, mainly cancer and auto-immune applications. The company plans to use the funds raised in December 2023 to advance multiple internal drug candidates through the preclinical proof-of-concept stage.
Current Investors
Alexandria Venture Investments, Charles River Laboratories, Amplitude
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.ability.bio
Verticals
Artificial Intelligence, HealthTech
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.